To view this page or post, please Log In Now or

Upgrade with one of the services below:

—

GeoInvesting Logo microcap stocks and research

Discovering tier one quality Microcap stocks and protecting investors from fraud for 13 years

Calls To Action

Calls to Actions include alerts on the stocks our team is buying and selling. You can choose to follow these moves to build your own portfolios or buy stocks at your convenience. About 1 CTA per week, so we don’t flood you with too much to think about.

Model Portfolios

Model portfolios focus on specific proven strategies to outperform the market. These custom portfolios are perfect for every level of experience and vary in strategy to appeal to different types of investors.

Premium Research

GeoInvesting provides institutional-grade research that’s affordable to the everyday investor. Unlike Wall Street investment banks, we don’t get paid by companies to talk about them. The GeoTeam’s research has powered over 11 years of investing success.

Education

We’re on a constant, daily search to improve our research methods and learn more about all things related to the stock market. Improve your stock picking skills and portfolio management from learning how we find winning management teams and avoid risky stocks.
Get Your Free Trial

Get one new biotech idea per weak from biotech experts with 30 years of experience

sentiment-advantageous

A future biotech catalyst announcement we believe is not likely to be negative, but supporting data from clinical studies may be inconsistent. Efficient treatment options also may already exist for patients. As a result, the market’s reaction to a positive catalyst could be minimal.

sentiment-pivotal

The drug or device typically addresses an unmet medical need with strong data from the company’s clinical studies supporting continued advancement or approval by the FDA. We believe the company or FDA announcement more than likely will be positive.

sentiment-superior

The drug or device offers a promising therapy for a disease with poor, if any, treatment options. The drug or device has received strong support from key opinion leaders, primarily because of excellent supporting data from clinical studies. We believe the upcoming company or FDA announcement is likely to be positive.

Learn More About SanaCurrents